Company: JUNS
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001641172-25-024684
Chunk: 24

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-08-19
Form: 10-Q
Item: Item 8
Chunk 24
---
 if our drug candidate receives marketing approval;

    ●
    the
    costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights
    and defending intellectual property-related claims;

    ●
    our
    ability to establish and maintain collaborations on favorable terms, if at all;

    ●
    our
    efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support
    the development of our drug candidate;

    ●
    the
    costs associated with being a public company; and

    ●
    the
    cost associated with commercializing our drug candidate, if it receives marketing approval.

26

See
“Risk Factors” included herein and in our 2024 Annual Report on Form 10-K for fiscal 2024 filed with the Securities and Exchange
Commission (the “SEC”) on March 28, 2025 for additional discussion of risks associated with our capital requirements.

Cash
Flows for the Six Months Ended June 30, 2025 and 2024

The
following table shows a summary of our cash flows for the six months ended June 30, 2025 and 2024.

    For the Six Months Ended June 30, 

    2025  
    2024 
  
    Net cash flows from operating activities  
    $(1,891,263) 
    $(172,627)
  
    Net cash flows from investing activities  
     -  
     - 
  
    Net cash flows from financing activities  
    $-  
    $159,000 
  
    Net increase (decrease) in cash  
    $(1,891,263) 
    $(13,627)

Net
Cash Flows From Operating Activities:

Net
cash used in operating activities during the six months ended June 30, 2025 was $1,891,263, as compared to net cash used in
operating activities of $172,627 for the six months ended June 30, 2024. The increase in net cash used in operating activities was
primarily attributable to the significant increase in net loss, which totaled $3,781,832 in 2025 compared to $320,977 in 2024. The
higher net loss was partially offset by increased non-cash adjustments, including $983,942 of stock-based compensation in 2025
compared to $632,300 in